This change will take effect February 24, 2012
Overview and Clinical Utility:
Effective February 24, 2012 PathGroup will implement the Optimized Serum Anti-Thyrogobulin Assay. This assay is intended to be used as an aid in the diagnosis of Hashimoto’s and Graves’ diseases which are autoimmune diseases affecting the thyroid gland.
Click Here to read more.